Century Therapeutics, Inc.

Century Therapeutics, Inc. (IPSC) reported significant financial improvement in FY 2025, achieving a net loss of -$9.6M compared to -$126.6M in FY 2024, driven by $109.2M collaboration revenue from the terminated Bristol-Myers Squibb agreement, up from $6.6M. Total operating expenses declined 12% to $126.4M from $144.7M, with R&D at $95.7M (down from $107.2M) and G&A at $24.0M (down from $33.2M), offset by $6.8M long-lived asset impairment and no goodwill impairment (vs. $4.3M prior). Loss from operations narrowed to -$17.3M from -$138.1M. Other income of $7.6M included $7.3M interest income. Balance sheet strengthened with $223.7M total assets, $120.8M current assets (cash $61.9M, short-term investments $55.3M), and $158.9M stockholders' equity. Cash used in operations was -$103.9M, offset by $107.5M investing inflows. Post-period, $126.7M net proceeds from January 2026 private placement extend runway into Q1 2029. Focus on IND-enabling studies for CNTY-813 (T1D) and CNTY-308 (autoimmune), with cash supporting preclinical advancement amid pipeline reprioritization.

Key Takeaways